{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-042270","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.495945+00:00","generated_at":"2026-05-21T15:08:47.289943+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeuroOne Q2 net loss narrows to $2.3M; gross margin up to 55.6%","bullets":["Q2 product revenue $1.4M flat YoY; H1 product revenue up 98% to $4.7M.","Q2 product gross margin 55.6% vs 28.3% YoY; FY25 guidance reaffirmed ($8-10M revenue).","Filed 510(k) for OneRF Trigeminal Nerve Ablation System for facial pain ahead of schedule; potential revenue in late CY2025.","Raised $8.2M net in oversubscribed institutional offering in April; cash $9.4M post-raise; debt-free.","Hired Dr. Parag Patil as Chief Medical Advisor and Emily Johns as General Counsel."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-042270","json":"https://secwatch.observer/filing/0001213900-25-042270.json","markdown":"https://secwatch.observer/filing/0001213900-25-042270.md","text":"https://secwatch.observer/filing/0001213900-25-042270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390025042270/0001213900-25-042270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390025042270/ea0241742-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T15:08:47.289943+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}